top of page
Search
  • modulation1

Modulation Therapeutics Announces receipt of a peer reviewed Fast Track SBIR award

Updated: Apr 4

February 2023

Modulation Therapeutics Announces receipt of a peer reviewed Fast Track SBIR award from the National Institutes of Health and the National Cancer Institute to complete research with MTI-301, a First in Class SCD-1 inhibitor for treating multiple cancers.

The FastTrack SBIR award will be funded in 2 milestone driven phases totaling up to $2.4M supporting both preclinical and first in human phase I clinical studies to assess the safety, tolerability, and pharmacokinetics of MTI-301, a Stearoyl CoA desaturase 1 (SCD1) inhibitor, as a therapeutic strategy for patients with advanced solid tumors in breast, liver, gastrointestinal and genitourinary cancers.

24 views

Recent Posts

See All
bottom of page